Você procurou por: 6 months to 1 year after training (Inglês - Turco)

the maximum stay is granted within 6 months (2 months to citizens of russia and ukraine).
maksimum kalış süresi 6 ay içinde verilir (rusya ve ukrayna vatandaşları 2 ay).

witnesses and storage samples of finished products should be stored at least 1 year after the expiry date of the product.
bitmiş ürün şahit ve saklama numuneleri, ürüne ait son kullanma tarihinden en az 1 yıl sonrasına kadar saklanmalıdır.

consultant agrees that for a period of one (1) year after termination of this agreement, consultant shall not:
danışman, bu anlaşmanın feshi sonrasında bir (1) yıl süresi boyunca:

a rapid respiratory rate is defined as greater than 60 breaths per minute in children under 2 months old, 50 breaths per minute in children 2 months to 1 year old, or greater than 40 breaths per minute in children 1 to 5 years old.
hızlı solunum hızı 2 aylıktan küçük çocuklarda dakikada 60 soluktan daha fazlası, 2 ay ila 1 yaş arası çocuklarda dakikada 50 soluk veya 1 ila 5 yaş arası çocuklarda dakikada 40 soluktan fazlası olarak tanımlanmıştır .

it is further described as either early (less than 1 year after secondary syphilis) or late (more than 1 year after secondary syphilis) in the united states.
ayrıca amerika birleşik devletleri’nde, erken (ikincil frengiden sonra 1 yıldan az) ya da geç (ikincil frengiden sonra 1 yıldan fazla) olarak tanımlanmıştır.

also this week: the world bank approves a 23m-euro investment loan for macedonia. up to 1. 5 billion euros in assistance might be needed for kosovoduring the first three years after the status settlement, eu enlargement commissioner olli rehn told the european parliament in brussels.
bu hafta ayrıca: dünya bankası makedonya için 23 milyon avroluk yatırım kredisini onayladı. ab'nin genişlemeden sorumlu Üyesi olli rehn brüksel'de avrupa parlamentosu'na hitaben yaptığı konuşmada, statü belirlendikten sonraki üç yıl boyunca kosova 'ya 1, 5 milyar avroya kadar yardım gerekebileceğini söyledi.

heading: low dose aspırın assocıated wıth a lower rısk of hepatocellular carcınoma sub heading: results of a study conducted among adults with chronic viral hepatitis İn sweden article text: worldwide, more than 500,000 cases of incident hepatocellular carcinoma are diagnosed each year, related primarily to chronic infection with hepatitis b or hepatitis c virus. although the incidences of hepatocellular carcinoma and liver-related death are reduced with hepatitis b viral suppression or hepatitis c eradication, they nonetheless persist in high-risk patients, including those with advanced fibrosis. thus, an urgent need remains to develop effective strategies to prevent hepatocellular carcinoma and reduce mortality from cirrhosis. three prior observational studies of this issue lacked detailed data regarding key determinants of hepatic outcomes, including underlying viral hepatitis, cirrhosis, and use of antiviral medication. moreover, information about aspirin-related bleeding events from an unselected population of patients with established chronic viral hepatitis would be valuable. the use of low-dose aspirin the study team examined the use of low-dose aspirin (≤160 mg) in relation to incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding among adults in sweden with confirmed chronic hepatitis b or hepatitis c infection. the investigators identified 50,275 adults who were diagnosed with chronic hepatitis b or hepatitis c from 2005 through 2015 and who did not have a history of aspirin use. in total 14,205 patients who were starting to take low-dose aspirin were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. with a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among non-users of aspirin (difference, −4.3 percentage points; 95% confidence interval [ci], −5.0 to −3.6; adjusted hazard ratio [hr], 0.69; 95% ci, 0.62 to 0.76). this inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hrs were 0.90 (95% ci, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% ci, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% ci, 0.42 to 0.70) for 5 or more years of use. ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, −6.9 percentage points [95% ci, −8.1 to −5.7]; adjusted hr 0.73 [95% ci, 0.67 to 0.81]). however, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and non-users of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% ci, −0.6 to 2.4). the authors concluded that in this registry study among adults with chronic viral hepatitis in sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. the findings were consistent regardless of sex, cause of hepatitis, or underlying compensated cirrhosis, which suggests that the benefits of aspirin may apply to a broad at-risk population. the results support the need for randomised clinical trials. referans: simon tg, duberg a-s, aleman s, et al. association of aspirin with hepatocellular carcinoma and liver-related mortality. n engl j med 2020; 382:1018-1028 doi: 10.1056/nejmoa1912035
başlık: düşük dozlu aspırın, hepatoselüler karsinoma alt riskiyle asosiye edildi alt başlık: İsveç'te kronik viral hepatitli yetişkinler arasında yapılan bir Çalışmanın sonuçları, makale: dünya çapında her yıl 500.000'den fazla hepatosellüler karsinom vakası teşhis edilmektedir. hepatit b veya hepatit c virüsü ile kronik enfeksiyon. hepatelüler karsinom ve karaciğerle ilişkili ölüm insidansı, hepatit b viral supresyonu veya